Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PBF-1129 |
Synonyms | |
Therapy Description |
PBF-1129 inhibits the adenosine A2B receptor (ADORA2B), which may lead to tumor microenviroment modulation and inhibition of tumor growth and metastasis (Journal of Thoracic Oncology, Jan 2017 12(Suppl 1):S1013). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PBF-1129 | PBF1129|PBF 1129 | Adenosine Targeting 23 | PBF-1129 inhibits the adenosine A2B receptor (ADORA2B), which may lead to tumor microenviroment modulation and inhibition of tumor growth and metastasis (Journal of Thoracic Oncology, Jan 2017 12(Suppl 1):S1013). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03274479 | Phase I | PBF-1129 | PBF-1129 in Patients With NSCLC | Active, not recruiting | USA | 0 |